- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
Frontage’s Bioanalytical Team is highly experienced in developing, qualifying, and validating biomarker assays. Our biomarker assay services provide accurate, reliable information. We can apply traditional and newer ELISA platforms as well as ultra-sensitive detection capabilities (Quanterix Simoa) for quantitation in the femtogram/mL range including single and multiplex analysis in various disease categories.
When biomarkers are present at extremely low levels in the early stages of physiological abnormalities (i.e. well before the onset of disease symptoms) or when they are downregulated by therapeutic intervention, detection and quantification can enable early diagnosis and prediction of therapeutic effectiveness. However, too often traditional assay platforms cannot meet the required assay sensitivity needed. The sensitivity of the Quanterix Simoa analyzer makes it the instrument of choice for ultra-sensitive analysis of biomarkers.
Our biomarker scientists have developed and validated a large number of biomarker assays for pharmaceutical and biotech companies. We are proud to become a benchmark in the field and have a significant impact on our clients using our expertise and state-of-the-art technology to advance/monitor drug development. We have also published novel biomarker assays developed in-house to share our expertise with the industry. With the addition of new technologies such as ELLA and Luminex for biomarker analysis, we believe we will continue as a top-notch provider of biomarker assay services in the years to come.